This company has received 510(k) clearance to expand the clinical use of its Access AccuTnI troponin I assay. Risk stratification involves categorizing patients with unstable coronary disease into high and lower risk groups, helping to identify those patients who may require urgent attention, and who are likely to benefit most from more aggressive therapy, such as early invasive procedures.
AccuTnI provides results in about 12 minutes. It is available on the Access and Access 2 immunoassay systems, and on the Synchron LXi 725 chemistry-immunoassay system.
Beckman Coulter
www.CLPmag.com
Keywords: cardiac marker, troponin
